Evolving perspectives in Wilson disease: Diagnosis, treatment and monitoring

Current Gastroenterology Reports

Volumn 14, Issue 1, 2012, Pages 1-7

  Weiss, Karl Heinz ^a   Stremmel, Wolfgang ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

ATP7B; Copper deficiency; Copper overload; D penicillamine; Genetic testing; Liver; Overchelation; Trientine; Wilson Disease; Wilson's disease; Zinc therapy

Indexed keywords

CERULOPLASMIN; COPPER; PENICILLAMINE; TETRATHIOMOLYBDATE AMMONIUM; TRIENTINE; ZINC DERIVATIVE;

ANEMIA; ARTICLE; ATP7B GENE; BONE MARROW TOXICITY; COPPER DEFICIENCY; COPPER METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ELASTOSIS; GASTRITIS; GENE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION; LUPUS LIKE SYNDROME; MONOTHERAPY; MUTATIONAL ANALYSIS; NEPHROTOXICITY; NEUROLOGIC EXAMINATION; PATIENT MONITORING; PROTEIN BLOOD LEVEL; TREATMENT FAILURE; WILSON DISEASE;

ADENOSINE TRIPHOSPHATASES; CATION TRANSPORT PROTEINS; HEPATOLENTICULAR DEGENERATION; HUMANS; MONITORING, PHYSIOLOGIC;

EID: 84857633568     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-011-0227-3     Document Type: Article

References (67)

1. A Ala AP Walker K Ashkan, et al. 2007 Wilson's disease Lancet 369 9559 397 408 17276780 10.1016/S0140-6736(07)60196-2 1:CAS:528:DC%2BD2sXht1OrsLc%3D (Pubitemid 46177228)
2. JD Gitlin 2003 Wilson disease Gastroenterology 125 6 1868 77 14724838 10.1053/j.gastro.2003.05.010 (Pubitemid 37500450)
3. PA Lang M Schenck JP Nicolay, et al. 2007 Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide Nat Med 13 2 164 70 17259995 10.1038/nm1539 1:CAS:528:DC%2BD2sXhsVyktbc%3D
4. H Zischka J Lichtmannegger S Schmitt, et al. 2011 Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease J Clin Invest 121 4 1508 18 21364284 10.1172/JCI45401 This study suggest that mitochondria is a pivotal target of copper toxicity. Zischka and co workers also show that chelating agents directly restore copper induced intra-mitochandial crosslinking
5. Gromadzka G, Rudnicka M, Chabik G, et al. Genetic variability in the methylenetetrahydrofolate reductase gene (MTHFR) affects clinical expression of Wilson's disease. J Hepatol. 2011.
6. KH Weiss U Merle M Schaefer, et al. 2006 Copper toxicosis gene MURR1 is not changed in Wilson disease patients with normal blood ceruloplasmin levels World J Gastroenterol 12 14 2239 42 16610028 1:CAS:528:DC%2BD28XltFamt70%3D
7. I Simon M Schaefer J Reichert, et al. 2008 Analysis of the human Atox 1 homologue in Wilson patients World J Gastroenterol 14 15 2383 7 18416466 10.3748/wjg.14.2383 1:CAS:528:DC%2BD1cXosVagt7k%3D (Pubitemid 351877610)
8. Weiss KH, Runz H, Noe B, et al. Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease. J Inherit Metab Dis. 2010.
9. U Merle W Stremmel R Gessner 2006 Influence of homozygosity for methionine at codon 129 of the human prion gene on the onset of neurological and hepatic symptoms in Wilson disease Arch Neurol 63 7 982 5 16831968 10.1001/archneur.63.7.982 (Pubitemid 44036301)
10. P Ferenci A Czlonkowska U Merle, et al. 2007 Late-onset Wilson's disease Gastroenterology 132 4 1294 8 17433323 10.1053/j.gastro.2007.02.057 1:CAS:528:DC%2BD2sXlslKrur8%3D This landmark paper demonstrates that WD is not only a pediatric disorder and advanced age does not exclude the diagnosis (Pubitemid 46627596)
11. EA Roberts ML Schilsky 2008 Diagnosis and treatment of Wilson disease: an update Hepatology 47 6 2089 111 18506894 10.1002/hep.22261 1:CAS:528: DC%2BD1cXotVagtL4%3D (Pubitemid 351945575)
12. P Ferenci K Caca G Loudianos, et al. 2003 Diagnosis and phenotypic classification of Wilson disease Liver Int 23 3 139 42 12955875 10.1034/j.1600-0676.2003.00824.x This landmark paper provides a most important diagnostic scoring system that still defines the diagnostic work-up for WD (Pubitemid 37265785)
13. KH Weiss DN Gotthardt D Klemm, et al. 2011 Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease Gastroenterology 140 4 1189 1198.e1 21185835 10.1053/j.gastro.2010.12.034 1:CAS:528: DC%2BC3MXjvVOktr0%3D Based on this large cohort study we suggest the concept of "non response to zinc therapy" in hepatic patients. Elevation of transaminases and increasing copper urinary excretion under zinc maintainance therapy might indicate an inadaquate treatment response and a chelating agent should be reintroduced into treatment
14. U Merle C Eisenbach KH Weiss, et al. 2009 Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson's disease J Hepatol 51 5 925 30 19720421 10.1016/j.jhep.2009.06.022 1:CAS:528:DC%2BD1MXht1CqurvN
15. DS Yuan R Stearman A Dancis, et al. 1995 The Menkes/WD gene homologue in yeast provides copper to a ceruloplasmin-like oxidase required for iron uptake Proc Natl Acad Sci USA 92 7 2632 6 7708696 10.1073/pnas.92.7.2632 1:CAS:528:DyaK2MXksl2rs78%3D
16. JB Tu RQ Blackwell 1967 Studies on levels of penicillamine-induced cupriuresis in heterozygotes of Wilson's disease Metabolism 16 6 507 13 6028804 10.1016/0026-0495(67)90079-0 1:CAS:528:DyaF2sXks1agu7o%3D
17. C Martins da Costa D Baldwin B Portmann, et al. 1992 Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease Hepatology 15 4 609 15 1551638 10.1002/hep.1840150410 1:STN:280:DyaK383gtFOktg%3D%3D
18. A Dhawan RM Taylor P Cheeseman, et al. 2005 Wilson's disease in children: 37-year experience and revised King's score for liver transplantation Liver Transpl 11 4 441 8 15776453 10.1002/lt.20352 (Pubitemid 40533213)
19. E Nicastro G Ranucci P Vajro, et al. 2010 Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease Hepatology 52 6 1948 56 20967755 10.1002/hep.23910
20. P Ferenci P Steindl-Munda W Vogel, et al. 2005 Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease Clin Gastroenterol Hepatol 3 8 811 8 16234011 10.1016/S1542-3565(05)00181-3 1:CAS:528:DC%2BD2MXhtVWjtLnO (Pubitemid 41116735)
21. Moller LB, Horn N, Jeppesen TD, et al. Clinical presentation and mutations in Danish patients with Wilson disease. Eur J Hum Genet. 2011.
22. L Wan CH Tsai CM Hsu, et al. 2010 Mutation analysis and characterization of alternative splice variants of the Wilson disease gene ATP7B Hepatology 52 5 1662 70 20931554 10.1002/hep.23865 1:CAS:528:DC%2BC3cXhsFOnsrrK
23. PV van den Berghe JM Stapelbroek E Krieger, et al. 2009 Reduced expression of ATP7B affected by Wilson disease-causing mutations is rescued by pharmacological folding chaperones 4-phenylbutyrate and curcumin Hepatology 50 6 1783 95 19937698 10.1002/hep.23209
24. J Petrasek M Jirsa J Sperl, et al. 2007 Revised King's College score for liver transplantation in adult patients with Wilson's disease Liver Transpl 13 1 55 61 17154398 10.1002/lt.20920 (Pubitemid 46099974)
25. H Nazer RJ Ede AP Mowat, et al. 1986 Wilson's disease: clinical presentation and use of prognostic index Gut 27 11 1377 81 3792921 10.1136/gut.27.11.1377 1:STN:280:DyaL2s%2FotFGiuw%3D%3D (Pubitemid 17175689)
26. W Stremmel KW Meyerrose C Niederau, et al. 1991 Wilson disease: clinical presentation, treatment, and survival Ann Intern Med 115 9 720 6 1929042 1:STN:280:DyaK38%2FislamtA%3D%3D
27. R Bruha Z Marecek L Pospisilova, et al. 2011 Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation Liver Int 31 1 83 91 20958917 10.1111/j.1478-3231.2010.02354.x 1:CAS:528:DC%2BC3MXjsFehtw%3D%3D
28. V Medici VG Mirante LR Fassati, et al. 2005 Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders Liver Transpl 11 9 1056 63 16123950 10.1002/lt.20486 (Pubitemid 41341754)
29. KH Weiss D Gotthardt J Schmidt, et al. 2007 Liver transplantation for metabolic liver diseases in adults: indications and outcome Nephrol Dial Transplant 22 Suppl 8 viii9 viii12 17890269 10.1093/ndt/gfm658
30. IH Scheinberg ME Jaffe I Sternlieb 1987 The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease N Engl J Med 317 4 209 13 3600712 10.1056/NEJM198707233170405 1:STN:280:DyaL2s3lvVSrtg%3D%3D (Pubitemid 17103102)
31. JM Walshe AK Dixon 1986 Dangers of non-compliance in Wilson's disease Lancet 1 8485 845 7 2870324 10.1016/S0140-6736(86)90949-9 1:STN:280: DyaL287ntlOgsQ%3D%3D (Pubitemid 16128959)
32. GJ Brewer GM Hill AS Prasad, et al. 1983 Oral zinc therapy for Wilson's disease Ann Intern Med 99 3 314 9 6614680 1:STN:280:DyaL3szgs1yltg%3D%3D
33. TU Hoogenraad R Koevoet EG de Ruyter 1979 Korver, Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration) Eur Neurol 18 3 205 11 477692 10.1159/000115077 1:STN:280:DyaL3c%2FgtlKlsg%3D%3D (Pubitemid 9237779)
34. GM Hill GJ Brewer AS Prasad, et al. 1987 Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens Hepatology 7 3 522 8 3570163 10.1002/hep.1840070318 1:STN:280:DyaL2s7pt1Ckuw%3D%3D (Pubitemid 17073159)
35. RJ Cousins 1985 Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin Physiol Rev 65 2 238 309 3885271 1:CAS:528:DyaL2MXktlGitLo%3D (Pubitemid 15081126)
36. A Czlonkowska B Tarnacka JC Moller, et al. 2007 Unified Wilson's Disease Rating Scale-a proposal for the neurological scoring of Wilson's disease patients Neurol Neurochir Pol 41 1 1 12 17330175 (Pubitemid 46390712)
37. B Leinweber JC Moller A Scherag, et al. 2008 Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease Mov Disord 23 1 54 62 17960799 10.1002/mds.21761 (Pubitemid 351281218)
38. JM Walshe 1956 Wilson's disease; new oral therapy Lancet 270 6906 25 6 13279157 10.1016/S0140-6736(56)91859-1 1:STN:280:DyaG28%2FjtFaqug%3D%3D
39. JM Walshe 1973 Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride Q J Med 42 167 441 52 4728043 1:CAS:528:DyaE2cXivFc%3D
40. RJ Grand GF Vawter 1975 Juvenile Wilson disease: histologic and functional studies during penicillamine therapy J Pediatr 87 6 PT 2 1161 70 1185415 1:STN:280:DyaE28%2Fkslyltg%3D%3D
41. JY Lau CL Lai PC Wu, et al. 1990 Wilson's disease: 35 years' experience Q J Med 75 278 597 605 2217665 1:STN:280:DyaK3M%2FhvVWrtw%3D%3D (Pubitemid 20214393)
42. A Czlonkowska J Gajda M Rodo 1996 Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate J Neurol 243 3 269 73 8936358 10.1007/BF00868525 1:STN:280:DyaK2s%2FptVCmsg%3D%3D (Pubitemid 26071990)
43. RS Dubois DO Rodgerson KM Hambidge 1990 Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine) J Pediatr Gastroenterol Nutr 10 1 77 81 2324883 10.1097/00005176-199001000-00015 1:STN:280: DyaK3c3hvVGhsQ%3D%3D (Pubitemid 20018112)
44. H Saito K Watanabe M Sahara, et al. 1991 Triethylene-tetramine (trien) therapy for Wilson's disease Tohoku J Exp Med 164 1 29 35 1926144 10.1620/tjem.164.29 1:STN:280:DyaK38%2Fitlalsw%3D%3D
45. GJ Brewer F Askari RB Dick, et al. 2009 Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine Transl Res 154 2 70 7 19595438 10.1016/j.trsl.2009.05. 002 1:CAS:528:DC%2BD1MXosVakt78%3D
46. GJ Brewer F Askari MT Lorincz, et al. 2006 Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease Arch Neurol 63 4 521 7 16606763 10.1001/archneur.63.4.521
47. GJ Brewer P Hedera KJ Kluin, et al. 2003 Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy Arch Neurol. 60 3 379 85 12633149 10.1001/archneur.60.3.379 (Pubitemid 36314363)
48. GJ Brewer V Johnson RD Dick, et al. 1996 Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy Arch Neurol. 53 10 1017 25 8859064 10.1001/archneur.1996.00550100103019 1:STN:280:DyaK2s%2Fht1anuw%3D%3D (Pubitemid 26340037)
49. GJ Brewer RD Dick V Johnson, et al. 1994 Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients Arch Neurol 51 6 545 54 8198464 10.1001/archneur.1994. 00540180023009 1:STN:280:DyaK2c3ls1ylsQ%3D%3D (Pubitemid 24169368)
50. GJ Brewer RD Dick V Yuzbasiyan-Gurkin, et al. 1991 Initial therapy of patients with Wilson's disease with tetrathiomolybdate Arch Neurol 48 1 42 7 1986725 10.1001/archneur.1991.00530130050019 1:STN:280:DyaK3M%2FpslegtQ%3D%3D
51. JM Walshe M Yealland 1993 Chelation treatment of neurological Wilson's disease Q J Med 86 3 197 204 8369040 1:STN:280:DyaK3s3kvVertA%3D%3D (Pubitemid 23120815)
52. GJ Brewer CA Terry AM Aisen, et al. 1987 Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy Arch Neurol 44 5 490 3 3579660 10.1001/archneur.1987.00520170020016 1:STN:280:DyaL2s3ht1KrsQ%3D%3D (Pubitemid 17061929)
53. FH Linn RH Houwen J van Hattum, et al. 2009 Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients Hepatology 50 5 1442 52 19731238 10.1002/hep.23182 1:CAS:528:DC%2BD1MXhsV2js7%2FK
54. TU Hoogenraad J Van Hattum CJ Van den Hamer 1987 Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients J Neurol Sci 77 2-3 137 46 3819764 10.1016/0022-510X(87)90116-X 1:STN:280: DyaL2s7ktVWhsQ%3D%3D (Pubitemid 17231288)
55. GJ Brewer RD Dick VD Johnson, et al. 1998 Treatment of Wilson's disease with zinc: XV long-term follow-up studies J Lab Clin Med 132 4 264 78 9794697 10.1016/S0022-2143(98)90039-7 1:CAS:528:DyaK1cXntFCltbs%3D (Pubitemid 28490259)
56. GJ Brewer V Yuzbasiyan-Gurkan DY Lee, et al. 1989 Treatment of Wilson's disease with zinc. VI. Initial treatment studies J Lab Clin Med 114 6 633 8 2592853 1:STN:280:DyaK3c%2FnvFalsQ%3D%3D (Pubitemid 20018040)
57. JM Walshe 1988 Diagnosis and treatment of presymptomatic Wilson's disease Lancet 2 8608 435 7 2900362 10.1016/S0140-6736(88)90423-0 1:STN:280: DyaL1czgtFKntA%3D%3D
58. JM Walshe NA Munro 1995 Zinc-induced deterioration in Wilson's disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet Arch Neurol 52 1 10 1 7826266 10.1001/archneur.1995.00540250012003 1:STN:280:DyaK2M7is1ygtQ%3D%3D
59. CJ Lang P Rabas-Kolominsky A Engelhardt, et al. 1993 Fatal deterioration of Wilson's disease after institution of oral zinc therapy Arch Neurol 50 10 1007 8 8280286 10.1001/archneur.1993.00540100008005 1:STN:280: DyaK2c%2FivFKhtQ%3D%3D (Pubitemid 23301243)
60. S Holscher B Leinweber H Hefter, et al. 2010 Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease Eur Neurol 64 2 83 7 20606453 10.1159/000316066
61. V Medici CP Trevisan R D'Inca, et al. 2006 Diagnosis and management of Wilson's disease: results of a single center experience J Clin Gastroenterol 40 10 936 41 17063115 10.1097/01.mcg.0000225670.91722.59 (Pubitemid 44690770)
62. JM Walshe 1989 Wilson's disease presenting with features of hepatic dysfunction: a clinical analysis of eighty-seven patients Q J Med 70 263 253 63 2602537 1:STN:280:DyaK3c%2FpvFOgsA%3D%3D (Pubitemid 19135600)
63. U Merle M Schaefer P Ferenci, et al. 2007 Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study Gut 56 1 115 20 16709660 10.1136/gut.2005.087262 1:CAS:528:DC%2BD2sXhtF2qsb4%3D (Pubitemid 46044897)
64. FP da Silva-Junior AA Machado LT Lucato, et al. 2011 Copper deficiency myeloneuropathy in a patient with Wilson disease Neurology 76 19 1673 4 21555737 10.1212/WNL.0b013e318219fac8
65. J Horvath P Beris E Giostra, et al. 2010 Zinc-induced copper deficiency in Wilson disease J Neurol Neurosurg Psychiatry 81 12 1410 1 20921535 10.1136/jnnp.2009.188896 1:STN:280:DC%2BC3cbnsFaktw%3D%3D
66. EE Santos Silva J Sarles JP Buts, et al. 1996 Successful medical treatment of severely decompensated Wilson disease J Pediatr 128 2 285 7 8636833 10.1016/S0022-3476(96)70412-2 1:STN:280:DyaK283jtF2itQ%3D%3D (Pubitemid 26065962)
67. FK Askari J Greenson RD Dick, et al. 2003 Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc J Lab Clin Med 142 6 385 90 14713890 10.1016/S0022-2143(03)00157-4 1:CAS:528:DC%2BD3sXhtVShs7zM (Pubitemid 38102022)